INTRODUCTION {#S1}
============

Metaplastic breast carcinomas constitute approximately 1% of invasive carcinomas and are characterized by histological evidence of epithelial to mesenchymal transition (EMT) towards spindle, squamous, and less frequently heterologous elements including chondroid and osseous differentiation ([@R31]). Metaplastic carcinomas are a subtype of triple negative breast cancer (TNBC) poorly responsive to chemotherapy with exhibit high propensity for distant metastasis ([@R2], [@R26]). Recent comprehensive genomic analyses revealed that metaplastic carcinomas belong to the mesenchymal-like subtype of TNBC, with a distinct transcriptional profile than other invasive breast carcinomas ([@R6], [@R11], [@R46]). However, the molecular determinants of metaplastic carcinomas needed to inform effective treatments are still incompletely understood.

Metaplasia is the reversible change in which one adult cell type is replaced by another adult cell type. Epithelial cells may undergo metaplasia through EMT, which during tumorigenesis results in the acquisition of molecular and phenotypic changes resulting in spindle morphology and dysfunctional cell-cell adhesion, leading to invasion and metastasis ([@R15]). Of all human cancers, metaplastic carcinomas provide the clearest evidence of morphological and molecular EMT with deregulation of genes involved in cell adhesion and low expression of claudins ([@R6], [@R11], [@R46]).

CCN6 (WISP3) is a secreted matricellular protein of the CCN family, which includes 6 members that play regulatory rather than structural roles in embryonic development, cell attachment, and growth ([@R19]). CCN proteins act in a cell and tissue-specific manner primarily through direct binding to cell surface receptors including integrins and by modulating the effect of extracellular growth factors on epithelial cells ([@R12], [@R23], [@R25], [@R32], [@R49]). We have shown that CCN6 is secreted by ductal epithelial cells in the breast, and that CCN6 downregulation in nontumorigenic breast cells is a robust inducer of EMT and is sufficient to confer growth factor independent survival and resistance to anoikis, a property of metastatic cancer cells ([@R12], [@R13], [@R25], [@R32], [@R33], [@R49]). Despite this knowledge, a direct role of CCN6 in breast tumorigenesis and the underlying mechanisms have remained elusive in part due to the lack of a physiologically relevant genetically engineered mouse model.

RESULTS {#S2}
=======

CCN6 protein is reduced in human metaplastic carcinomas {#S3}
-------------------------------------------------------

Based on our previous studies showing that CCN6 regulates the transition between epithelial and mesenchymal states in breast cells, we set out to investigate CCN6 expression in breast tissues including invasive carcinomas and metaplastic carcinomas. Immunohistochemical evaluation revealed that CCN6 level is significantly reduced in spindle metaplastic carcinomas compared to normal breast and invasive ductal carcinomas ([Fig.1A](#F1){ref-type="fig"}). All normal breast lobules examined, and 67% of invasive ductal carcinomas maintained high levels of CCN6, and 33% had low levels. This distribution was shifted in metaplastic carcinomas, among which 67.9% had low CCN6 expression ([Fig.1B](#F1){ref-type="fig"}).

Mammary epithelial specific *Ccn6* deletion causes abnormal mammary gland development {#S4}
-------------------------------------------------------------------------------------

To directly investigate whether loss of *Ccn6* *in vivo* triggers the development of carcinomas that recapitulate human metaplastic carcinomas, we generated a new model of epithelial cell specific *Ccn6* deletion in the mammary gland using Cre/loxp-mediated recombination ([Fig.2A-B](#F2){ref-type="fig"}). We specifically inactivated the *Ccn6* gene in the mammary epithelium, by intercrossing the floxed *Ccn6* mice with the MMTV-Cre mice. The offspring were genotyped using primers specific for various *Ccn6* alleles (i.e. floxed, wild type, and deleted) and with primers specific for Cre ([Fig.2C](#F2){ref-type="fig"}). We confirmed the presence of *Ccn6* deletion in the mammary glands by quantitative RT-PCR and Western blots using whole mammary gland protein extracts, and by immunohistochemistry in mammary gland tissue samples ([Fig.2D-F](#F2){ref-type="fig"}).

Our initial characterization studies show that pre-pubertal (5 week old) and pubertal (8 week old) *Ccn6^fl/fl^;MMTV-Cre* mice exhibit reduced numbers of TEBs and of bifurcated TEBs compared with controls ([Fig.3A-B](#F3){ref-type="fig"}, [Supplementary Fig.1A-D](#SD1){ref-type="supplementary-material"}). At 16 weeks adult virgin *Ccn6^fl/fl^;MMTV-Cre* mice display a significant reduction in mammary gland complexity in Carmine alum-stained whole mounts and histopathology compared to littermate controls ([Fig.3C-D](#F3){ref-type="fig"}, [Supplementary Fig.2A-C](#SD1){ref-type="supplementary-material"}). *Ccn6* deletion resulted in a hypoplastic ductal epithelium with significantly reduced ductal thickness. The ductal epithelial cells were flat compared to the tall columnar cells present in the control ducts ([Fig.3E-F](#F3){ref-type="fig"}). The ductal epithelial hypoplasia of *Ccn6^fl/fl^;MMTV-Cre* mice was highlighted by immunostaining with CK-18 and CK-5 marking luminal and basal cells, respectively. Consistent with the hypoplastic ductal phenotype of *Ccn6^fl/fl^;MMTV-Cre* mammary glands we detected reduced mitosis identified by pH3 immunostaining compared to controls ([Fig.3E](#F3){ref-type="fig"}). Despite these abnormalities, *Ccn6^fl/fl^;MMTV-Cre* dams were able to nurse their litters, and glands underwent post lactational involution similar to controls ([Fig.3A-C](#F3){ref-type="fig"}).

To assess the global impact of CCN6 ablation on mammary epithelial cell development *in vivo* in an unbiased fashion, isolated RNA from 8 week old virgin *Ccn6^fl/fl^;MMTV-Cre* mammary glands and littermate controls was subjected to transcriptional profiling. *Ccn6* deletion significantly altered the expression of \~180 unique transcripts with marked effects noted in gene ontologies associated with extracellular signaling, matrix-associated functions, and mammary gland lobule development including *Bmp8a, Acta1, Cxcl13*, and *Dmbt1* ([Fig.3G](#F3){ref-type="fig"}, [Supplementary Fig.4A-C](#SD1){ref-type="supplementary-material"}). Together, the results indicate that *Ccn6* is required for branching morphogenesis and proper development of the mammary ductal epithelium in virgin mice.

Deletion of *Ccn6* in the mammary epithelium results in abnormal age-related involution {#S5}
---------------------------------------------------------------------------------------

In humans, delayed age-related mammary gland involution has been associated with increased risk for breast cancer ([@R28], [@R36]). We found evidence of abnormal age-related involution in virgin *Ccn6^fl/fl^;MMTV-Cre* mice compared to controls. As expected, while at 8 months of age 1 of 4 (25%) control mice had foci of brown adipose tissue (BAT), all *Ccn6^fl/fl^;MMTV-Cre* mice examined had residual BAT in the mammary glands ([Fig.4A-B](#F4){ref-type="fig"}). Likewise, while at 8 months of age there were no residual TEBs in virgin control mice, TEBs persisted in 4 of 6 (66.7%) virgin *Ccn6^fl/fl^;MMTV-Cre* mice ([Fig.4C-D](#F4){ref-type="fig"}). Thus, *Ccn6* expression is required for proper age-related involution of the virgin murine mammary gland.

*Ccn6* is a breast tumor suppressor in mice {#S6}
-------------------------------------------

Thirteen of 18 (72.2%) *Ccn6^fl/fl^;MMTV-Cre* mice formed mammary carcinomas (age range 10--21 months, mean 15.5 months), compared to 3 of 24 (12.5%) of the *Ccn6^wt/wt^;MMTV-Cre* (Fisher's exact test *P* \< 0.005). The mammary carcinomas of *Ccn6^fl/fl^;MMTV-Cre* exhibit mitotically active elongated cells of high histological grade, remarkably similar to the spindle subtype of human metaplastic carcinomas ([Fig.5Aa-f](#F5){ref-type="fig"}). *Ccn6^fl/fl^;MMTV-Cre* mice tumors were highly invasive into the surrounding mammary tissues and skeletal muscle ([Fig.5Aa-f](#F5){ref-type="fig"}). The non-neoplastic mammary gland tissues of *Ccn6^fl/fl^;MMTV-Cre* mice display a variety of histological abnormalities including persistent TEBs, secretory hyperplasia, and atypical ductal hyperplasia similar to the human counterpart ([Fig.5B](#F5){ref-type="fig"}, [Table 1](#T1){ref-type="table"}).

Distant metastasis developed in 6 of 13 (46.2%) tumor bearing *Ccn6^fl/f^;MMTV-Cre* mice, 5 to the lungs, and 1 to the soft tissues of the neck, compared to none of the *Ccn6^wt/wt^;MMTV-Cre control mice*. To investigate the effect of *Ccn6* deletion in metastasis in greater detail, we crossed *Ccn6^fl/fl^;MMTV-Cre* mice with polyoma middle-T antigen (PyMT)-MMTV mice. PyMT-MMTV mice uniformly develop multifocal mammary tumors with a high incidence of pulmonary metastasis ([@R8]). Despite no differences in primary mammary tumor volume, female virgin *Ccn6^fl/fl^;MMTV-Cre/PyMT* mice showed a significant increase in the number of grossly evident lung metastasis compared to *Ccn6^wt/wt^;MMTV-Cre/PyMT* mice ([Fig.5C-D](#F5){ref-type="fig"}).

Mammary carcinomas of *Ccn6^fl/fl^;MMTV-Cre* mice share an 87-gene signature with human metaplastic breast carcinomas {#S7}
---------------------------------------------------------------------------------------------------------------------

We next sought to examine whether *Ccn6^fl/fl^;MMTV-Cre* mammary carcinomas recapitulate human metaplastic carcinoma phenotypes as defined by gene expression patterns. Transcriptional profiling of *Ccn6^fl/fl^;MMTV-Cre* mammary carcinomas using Affymetrix revealed 5,354 significantly deregulated gene transcripts compared to age-matched wild-type mammary gland controls. We included genes with a fold change of 2 or greater and an adjusted p-value of 0.05 or less, using a false discovery rate of 0.05 or less. We compared the gene profile of *Ccn6^fl/fl^;MMTV-Cre* tumors with a published human metaplastic breast carcinoma signature derived by comparing gene expression profiles of metaplastic carcinomas with profiles of all other breast cancers ([@R11]). By directly comparing the relative expression ratio of orthologous genes between human and mouse, we found that *Ccn6^fl/fl^;MMTV-Cre* tumors exhibit similarities with the gene expression activity of human metaplastic carcinomas. Of the 602 orthologous genes in the human metaplastic carcinoma signature, there were 87 (14.4%) shared genes concordantly up or down regulated with human metaplastic carcinomas (Fisher's exact test *p*=5×10^−11^, [Fig.6A-B](#F6){ref-type="fig"}).

In Gene Ontology analyses, the 87 shared orthologous genes fell into several functional groups. The top five enriched biological processes were morphogenesis of an epithelium, embryo development, lateral plasma membrane, cellular amino acid metabolic process, and very long chain fatty acid catabolic process ([Table 2](#T2){ref-type="table"}, [Suppl. Fig.5](#SD1){ref-type="supplementary-material"}). *Ccn6^fl/fl^;MMTV-Cre* tumors exhibited downregulated expression of *Cldn3, Cldn5, Cdh1, Krt19*, previously reported in human metaplastic carcinomas ([@R6], [@R11], [@R46]). Significantly, *Ddr1*, *Fzd3, Elf3*, *Stat5b, and Foxa1* are among the shared downregulated genes, while *Wnt10a, Hmga2, Hbegf, and Edil3* are among shared upregulated genes ([Fig.6B](#F6){ref-type="fig"}). While these genes are important for normal epithelial homeostasis and have been implicated in carcinogenesis, they have not been previously considered in the pathogenesis of metaplastic carcinoma.

In daily pathology practice, the diagnosis of metaplastic carcinoma is supported by detection of a combination of epithelial and mesenchymal proteins ([@R21], [@R37], [@R40], [@R42], [@R46]). *Ccn6^fl/f^;MMTV-Cre* mice tumors had a protein expression profile similar to human metaplastic carcinoma characterized by negative ER and HER-2/neu expression, reduced expression of epithelial markers E-cadherin and cytokeratin-18, and increased expression of the mesenchymal markers vimentin, and the human metaplastic carcinoma markers CD10 and p63 ([@R21], [@R38], [@R39]) ([Fig.6C](#F6){ref-type="fig"}). Taken together, these data document that *Ccn6* deletion in the mammary gland epithelium is sufficient to induce carcinomas with histological, immunophenotypic, and transcriptomic features that recapitulate human spindle metaplastic carcinomas.

DISCUSSION {#S8}
==========

Metaplastic carcinomas, and in particular those with spindle histopathology, are less responsive to chemotherapy than other TNBC ([@R10], [@R37]). Elucidation of the molecular underpinnings of this unusual but aggressive type of breast cancer is necessary to develop effective therapeutic strategies. Our previous identification of *Ccn6* frame shift mutations in human metaplastic carcinoma tissues ([@R9]) coupled with the observation that CCN6 expression is reduced or absent in clinical samples of metaplastic carcinoma raised the suspicion that *Ccn6* may be causally involved in their pathogenesis rather than just serve as a marker for these tumors. Our results demonstrate that genetic ablation of *Ccn6* in the mammary epithelium of mice induces the development of invasive tumors that recapitulate human metaplastic spindle carcinomas on their histopathology, transcriptional activity, and biological behavior.

Ample mechanistic and functional data support the importance of the process of EMT in human tumorigenesis, however, direct identification of cancer cells undergoing EMT in clinical cancer tissue samples has been challenging ([@R1]). Metaplastic carcinomas of the breast and other organs are the only human malignancies with overt EMT consisting of spindle cells and mesenchymal-like components, loss of epithelial and gain of mesenchymal marker proteins, and a distinctive transcriptional profile rich in genes involved in EMT ([@R6], [@R11], [@R46]).

CCN proteins are secreted extracellular matrix associated proteins that regulate stroma-epithelial cross-talk to influence angiogenesis, cell proliferation, invasion, adhesion and other important cell functions in a context-dependent manner ([@R12], [@R23], [@R25], [@R32], [@R49]). CCN6 mutations were reported in patients with progressive pseudorheumatoid dysplasia, and deregulated expression of CCN6 was found in colon and breast cancer ([@R16], [@R35]). However, global *Ccn6* deletion in transgenic mice revealed no discernible skeletal phenotype ([@R22]). In breast cancer, we have demonstrated that CCN6 regulates the transition between epithelial and mesenchymal states *in vivo* and *in vitro* ([@R12], [@R14], [@R20], [@R25]). CCN6 knockdown in nontumorigenic breast cells induces a spindle and invasive phenotype with inhibited expression of E-cadherin and cytokeratin, and upregulation of vimentin and EMT transcription factors ([@R12], [@R25]). In contrast, CCN6 overexpression in breast cancer cells reduces invasion and metastasis in xenograft models, and leads to a mesenchymal to epithelial transition (MET) ([@R14], [@R32]). Despite these data, proof that *Ccn6* deficiency results in mammary tumor development and the relevance of these data to human metaplastic carcinomas was unknown. The mammary epithelial cell-specific *Ccn6* knockout model developed here provides direct demonstration of an essential role for CCN6 in the pathogenesis of mammary carcinomas with overt EMT.

During mammary gland development, pre-pubertal and nulliparous adult *Ccn6^fl/fl^;MMTV-Cre* mice exhibit fewer mammary ducts and a hypoplastic breast epithelium with defective developmental patterns and reduced mitosis compared to littermate controls. The restricted development of the mammary glands of *Ccn6^fl/fl^;MMTV-Cre* mice highlights a role for *Ccn6* in mammary gland morphogenesis and may have implications for tumorigenesis. A similar phenotype has been reported after deletion of classical tumor suppressors including *Brca1 and Brca2* ([@R7], [@R27], [@R47]). Because *Ccn6*-related tumorigenesis is characterized by an initial growth disadvantage it is not unexpected that tumor formation occurs after a long latency, albeit with high frequency, as observed in *Brca1* conditional knockout mice ([@R47]).

The developmental delay in pre-pubertal *Ccn6*-deficient mice and the propensity to develop carcinomas in adult life may be linked to the deregulation of gene targets. Transcriptional profiling of *Ccn6* deleted versus *Ccn6* wild type pre-pubertal mammary glands uncovered a complex range of deregulated targets, especially those associated with mammary epithelial development. We noted a significant downregulation of *Dmbt1*, a glycoprotein of the scavenger receptor cysteine-rich (SRCR) family, with roles in immunity and cancer ([@R29]). *Dmbt1* was identified as a modifier of susceptibility to mammary tumors in Trp53+/− BALB/c breast cancer model ([@R5]), and *Dmbt1* polymorphisms are associated with increased risk of breast cancer ([@R44]).

In contrast with invasive ductal or lobular carcinomas of the breast, metaplastic carcinomas often lack an associated ductal carcinoma *in situ* component, and its precursors have not been identified in tissue samples ([@R42]). The conditional *Ccn6* knockout mice generated here shed light into the histological abnormalities that precede the development of spindle cell metaplastic carcinomas. Virgin *Ccn6^fl/fl^;MMTV-Cre* mammary glands failed to involute properly with age, as evidenced by abnormal persistence of residual TEBs and brown adipose tissue at 8 months of age, in contrast with the mammary glands of age-matched littermate control mice. Of note, defective age-related involution with persistent BAT has been reported in mammary glands from adult *Brca1* mutant mice prior to development of poorly differentiated carcinomas ([@R18]). These data are remarkable in light of recent studies showing that defective age-related involution in human mammary glands is significantly associated with increased risk for breast cancer development ([@R28], [@R36]). Postmenopausal women with delayed age-related mammary gland involution have a 3-fold increased risk of breast cancer compared with women with complete involution ([@R28], [@R36]). Collectively, our model provides insights into the role of *Ccn6* loss during preneoplastic progression and may have clinical implications for preventative strategies.

Our transcriptional profiling studies show that *Ccn6^fl/fl^;MMTV-Cre* tumors share an 87-gene signature with human metaplastic carcinomas ([@R11]). Among the 87 shared genes (10 up- and 77 are downregulated) are several that have been previously studied as markers of human metaplastic carcinoma including downregulated expression of *Cdh1, Cldn3, Cldn4*, and *Krt19* ([@R11], [@R21], [@R42], [@R48]). Also significantly overlapping with human metaplastic carcinomas are novel genes, which have not been previously studied in this context. Among the 3 top uregulated genes are *Hmga2, Igfbp2, and Hbegf. Hmga2* (high mobility group AT-hook 2) was previously reported to promote EMT and metastasis by activating the TGFβ receptor II signaling ([@R30]). *Igf2bp2 (p62/IMP2)*, a member of the family of insulin-like growth factor 2 mRNA binding proteins, promotes breast cancer cell migration and to reduce adhesion in TNBC cells ([@R24]). *Hbegf* (heparin binding EGF-like growth factor) induces breast cancer intravasation and metastasis ([@R50]). Among the most significantly downregulated genes shared between *Ccn6^fl/fl^;MMTV-Cre* tumors and human metaplastic carcinomas are *Foxa1, Spint1 and 2*, and *Ddr1*. *Foxa1*, an important regulator of the ERα and the androgen receptor, whose silencing increases invasion and induces an aggressive, basal-like breast cancer phenotype ([@R4]). *Spint 1 and 2* (hepatocyte growth factor activation inhibitors HAI-1 and HAI-2) are potent matriptase inhibitors reducing invasion and metastasis in TNBC ([@R34]). The Discoidin Domain Receptor 1 (*Ddr1*), a collagen-binding receptor tyrosine kinase, is associated with worse survival in women with TNBC ([@R45]). Elucidation the functional significance and underlying mechanism of these novel genes which were previously unconsidered in the context of metaplastic carcinoma, may lead to new diagnostic, prognostic, and therapeutic targets.

In conclusion, data presented herein establish that mammary epithelial cell loss of *Ccn6* triggers the development of spindle metaplastic carcinomas recapitulating human disease. We believe that this mouse model will be useful in understanding how *Ccn6* serves its breast cancer suppression function.

MATERIALS AND METHODS {#S9}
=====================

Construction of the targeting vector and generation of floxed *Ccn6* mice {#S10}
-------------------------------------------------------------------------

All animal experiments followed procedures approved by the UCUCA of the University of Michigan, protocol UCUCA \#PRO00005009. Mice with mammary epithelial-cell specific *Ccn6* deletion were generated using the Cre-Lox recombination system. The mouse chromosome 10 sequence of *mWisp3* gene was retrieved from the Ensembl database and used as reference. Using genomic DNA from FVB mice as a template, the 5' homology arm (\~5.6 kb), 3' homology arm (\~3.7 kb) and the conditional knockout region (\~4.5 kb, containing exons 2 and 3) of the *Ccn6* allele were generated by PCR using high fidelity Taq DNA polymerase. These fragments were cloned in the LoxFtNwCD or pCR4.0 vector; aside from the homology arms, the final vector also contained LoxP sequences flanking the conditional KO region (\~4.5 kb), Frt sequences flanking the Neo expression cassette (for positive selection of the electroporated ES cells), and a DTA expression cassette (for negative selection of the ES cells). The final vector was confirmed by both restriction digestion and end sequencing analysis. For southern blot analysis and identification of the ES positive for homologous recombination with single neo integration, 5' and 3' external probes were generated by PCR. 30 µg of NotI-linearized targeting vector DNA was electroporated into FVB ES cells and selected with 200 µg/ml G418 (Gibco, \#10131-035). The primary ES cell screening was performed with 3' PCR and distal LoxP PCR. Five potential targeted clones (A9, B7, B8, H1 and H6) were identified from one plate, which were expanded for further analysis. Upon completion of the ES clone expansion, additional Southern confirmation analysis was performed. Based on this analysis, two out of the five expanded clones (B7 and B8) were confirmed for homologous recombination with single neo integration. Flp electroporation was performed on these clones, and subsequent Neo deleted clones were identified and confirmed by PCR upon expansion. Confirmed Neo-deleted ES cell clones were injected into mouse C57BL/6NTac blastocysts and breeding of the male chimeras to wild-type FVB females resulted in germline transmission. Heterozygous *Ccn6*^fl/wt^ mice were crossed with MMTV-Cre line A mice on an FVB background (kind gift of Dr. Stephen Weiss). Generation of the targeting vector, cloning, electroporation into embryonic stem cells, and breeding of chimeras to F1 generation mice was carried out by Taconic Biosciences, Inc.

*Ccn6^fl/fl^;MMTV-Cre* mice were intercrossed with MMTV-PyMT mice (FVB/n) to generate breeding cohorts. After weaning, female mice were examined twice a week for the development of mammary tumors by palpation. Tumors were then measured once per week until tumors reached 1 cm^3^, after which tumors were measured twice per week until mice were sacrificed. Mice were sacrificed when tumors reached 2 cm^3^, to control for tumor size when considering the effect of *Ccn6* loss on metastasis. All mammary tumors were excised, weighed, and collected for histology and RNA isolation as described elsewhere in the methods. Lungs were inflated with 10% NBF, macrometastases were counted immediately by eye, and then lobes were separated and placed in a cassette for histology.

Genotyping {#S11}
----------

Mice and embryos were genotyped by PCR analysis of genomic DNA from mouse tail samples. Isolation of genomic DNA was done using the DNeasy Blood and Tissue Kit (Qiagen, \#69506) according to manufacturer's instructions. Primers used to genotype CCN6 alleles were P1, 5'-TTC AAA ATT GTG GGA ATA GCT CCA GTA TT-3'; P2 5'-CCA TTG ATA CTG GTT GAG AAC ACA GTG AG-3'. Amplification with these primers results in a 196-bp fragment from the CCN6^WT^ allele and a 344-bp fragment from the CCN6^fl^ allele after neo deletion. Primers used to genotype CRE alleles were P1, 5'-GGT TCT GAT CTG AGC TCT GAG TG-3'; P2 5'-CAT CAC TCG TTG CAT CGA CCG G-3'. PCR was performed for 35 cycles of 94°C (30 sec), 56°C (90 sec), and 72°C (60 sec) for amplification of *Ccn6* and Cre alleles.

Animal studies {#S12}
--------------

All procedures were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at the University of Michigan (UCUCA \#PRO00005009). Mice were housed in standard conditions, at 23°C, with a 14/10 h light/dark cycle, and food and water supplied ad libitum. We observed no difference among any of the control mice genotypes when considering histological and morphological phenotype, immunoblots or qPCR data; therefore the wild-type control groups presented here consist of a mixture of all of the genotypes.

Mice were euthanized and the left \# 4 inguinal mammary gland was excised, spread onto a microscope slide and immediately fixed in Carnoy's fixative for 5 hours. Subsequently, the tissue was washed in graded alcohol solutions (70, 50, 25%; 15 min each) and finally in ddH~2~O for 5 min. Staining was carried out overnight in carmine alum stain. The tissue was then dehydrated in graded alcohol solutions (70, 80, 95, and 100%; 15 min each), cleared in xylene overnight, and mounted using Permount. Whole mounts were observed under a Leica MZFL III Stereo/Dissecting microscope (Leica Microsystems GmbH, Wetzlar, Germany), and digital images were recorded using an Olympus DP-70 digital camera. A portion of the mammary gland was placed in a cassette and fixed in 10% neutral buffered formalin for 48 h at room temperature. After fixation, tissues were transferred to 70% ethanol, embedded in paraffin, sectioned and stained with H&E for routine histological examination, or left unstained for later immunohistochemistry.

Microarray analysis and statistics {#S13}
----------------------------------

RNA was isolated from either 8 week old knockout and control mouse mammary glands (n=4 for each group), or mammary tumors from *Ccn6^fl/fl^*;MMTV-Cre mice and age matched *Ccn6*^wt/wt^;MMTV-Cre control mammary glands (n=4 for each group). Isolated RNA was processed on a Mouse Gene ST 2.1 strip assay at the University of Michigan Microarray Core using the Affy Plus Kit (Affymetrix). For statistical analyses, robust multi-array average (RMA) was used to fit log2 expression values to probesets using the oligo package of bioconductor ([@R17]). Linear models were fit using the limma package of bioconductor to identify differentially expressed probesets ([@R43]). Arrays were weighted based on a gene-by-gene update algorithm designed to downweight genes deemed less reproducible ([@R41]). P-values were adjusted using false discovery rate (FDR) ([@R3]). Comparison to human metaplastic carcinoma was done using data from a custom Agilent array of 12 patient samples developed at the University of North Carolina, GEO\# GSE10885 ([@R11]). The mouse Affymetrix array data were compared to the human Agilent array data to identify the matching gene symbols between the arrays; further, a list of the gene symbols that were significantly deregulated in the same direction in both arrays was compiled. Statistical analysis of the resulting contingency table was done using a Fisher's exact test.

Immunoblots {#S14}
-----------

Whole mammary tissue sample (50 mg) was weighed from the most distal portion of the \#4 inguinal mammary gland and lysed in RIPA lysis buffer (Thermo-Fisher Scientific) with protease and phosphatase (Thermo-Fisher Scientific) inhibitors at 100x dilution in Precellys 2mL tissue homogenizing mixed beads kit (Cayman Chemical) using a Precellys homogenizer at 6500 rpm (2 cycles of 15 sec motion-15 sec rest). Immunoblots were carried out with 40µg of total protein. Membranes were blocked in TBS-T (Bio-Rad, with 0.05% Tween20) with 4% milk (Bio-Rad, \#170-6404) and incubated with primary antibodies in TBS-T at 4°C overnight. Membranes were stained with Ponceau-S solution (Sigma-Aldrich) to confirm equal loading. Anti-CCN6 (Santa Cruz Biotechnology, \#SC-25443) was the primary antibody.

Immunohistochemical studies {#S15}
---------------------------

Immunohistochemistry of human breast cancer tissue samples was performed in 110 cases of invasive breast carcinoma comprising 82 invasive ductal and 28 metaplastic carcinomas obtained with University of Michigan IRB approval (HUM00050330). Hematoxylin and eosin stained samples were histologically evaluated and 5 µ thick sections were immunostained using anti-CCN6 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) following published protocols ([@R12]). CCN6 expression was evaluated as either low or high based on intensity of staining and percentage of cells staining ([@R12]).

To immunostain mouse mammary glands formalin-fixed, paraffin-embedded sections were cut at 5 µm and rehydrated with water. Heat induced epitope retrieval was performed with FLEX TRS High pH Retrieval Buffer (9.01) for CCN6, for 20 minutes (Dako, Carpinteria, CA). Immunohistochemical staining was performed using Peroxidase for 5 min to quench endogenous peroxidases, followed by incubation for 60 minutes with one of the following antibodies: CCN6 (Santa Cruz Biotechnology), CK-18 (Abcam), E-cadherin (BD Biosciences), Vimentin (BD Biosciences), CD10 (BD Biosciences), p63 (Santa Cruz Biotechnology), ERα (Santa Cruz Biotechnology), and HER-2/neu (Santa Cruz Biotechnology). The EnVision + Rabbit HRP System was used for detection (DakoCytomation). DAB chromagen was then applied for 10 minutes. Slides were counterstained with hematoxylin for 5 seconds and then dehydrated and coverslipped. For quantification, three representative areas from three *Ccn6^fl/fl^*;MMTV-Cre and three *Ccn6^wt/wt^*;MMTV-Cre mice were counted for epithelial cells that stained positive for the protein of interest and calculated as a percentage of the total number of epithelial cells; all counts were done blind to genotype by two separate investigators.

Statistics {#S16}
----------

Data are expressed as mean ± SD. All experiments were repeated at least 3 times with similar results. The 2-tailed Student's *t* test was performed to determine the probability of statistically significant difference (*P* values) and recorded in figure legends. A P value less than 0.05 was considered statistically significant.
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![CCN6 protein is reduced in human spindle metaplastic carcinomas of the breast compared to invasive ductal carcinoma and normal breast lobules\
**A**. images of a normal breast lobule, an invasive ductal carcinoma with no special features, and a spindle metaplastic carcinoma stained with hematoxylin and eosin (H&E) and CCN6 immunostaining (magnification 400x). **B**. Invasive metaplastic and ductal carcinomas with high or low CCN6 protein. Chi square test *P*=0.0018. (Scale bars, 20 µm.)](nihms815638f1){#F1}

![Conditional deletion of *Ccn6* in the mammary epithelium using the Cre-Lox system\
**A**. Mouse *Ccn6* containing exons 2 and 3. Pictured: wild type allele; targeted allele after homologous recombination in ES cells; the floxed allele in which exons 2 and 3 are flanked by loxP sites and the neomycin cassette has been excised; the allele in which exons 2 and 3 have been deleted in *Ccn6^fl/fl^*;MMTV-Cre mice. 5' homology arm (\~5.6 kb), 3' homology arm (\~3.7 kb) and cKO region (\~4.5 kb) are marked. **B**. Embryonic stem cell clones were screened for recombination of the targeting vector at the 5′ (BamHI) or 3′ (NheI) ends. **C**. Example of genotyping results demonstrating amplification of the *Ccn6^wt^* and *Ccn6^fl/fl^* alleles. **D**. Relative expression of *Ccn6* at the mRNA level as assessed by qt-PCR in 8 week-old mice and 4 month old mice (n≥3 mice per genotype per timepoint; p\<0.01 for 8 weeks old, p\<0.05 for 4 months old). **E**. Immunoblot for Ccn6 in representative samples from different timepoints in *Ccn6^fl/fl^;MMTV-Cre* and littermate control (Ccn6^wt/wt^;MMTV-Cre) mice. **F**. Immunohistochemistry showing the expression of Ccn6 protein in 4 month-old mice mammary glands (at least 3 mice were stained from each genotype). (Scale bars, 20 µm.)](nihms815638f2){#F2}

![Mammary epithelial cell specific *Ccn6* knockout leads to defects in branching and ductal epithelial hypoplasia\
**A**. Representative pictures of the distal end of invading ducts in pubertal *Ccn6^wt/wt^;MMTV-Cre* and *Ccn6^fl/fl^;MMTV-Cre* mice, 2x magnification. Inset of a normal bifurcated duct giving rise to two TEBs in *Ccn6^wt/wt^;MMTV-Cre*, compared to a duct that failed to normally bifurcate in an *Ccn6^fl/fl^;MMTV-Cre* mouse (20x magnification). **B**. Quantification of the average number of TEBs and bifurcated TEBs of *Ccn6^fl/fl^;MMTV-Cre* and littermate controls. **C**. Representative mammary whole mounts from 4 month-old *Ccn6^fl/fl^;MMTV-Cre* and *Ccn6^wt/wt^;MMTV-Cre* mice. **D**. Quantification of the number of ducts and acini at 5, 10 and 15 mm from the mammary lymph node. **E**. Representative images of *Ccn6^fl/fl^;MMTV-Cre* and *Ccn6^wt/wt^;MMTV-Cre* glands stained with H&E and with antibodies against the indicated proteins. **F**. Ductal epithelial thickness was quantified using image J. **G**. Gene ontology (GO) analysis of *Ccn6^fl/fl^*;*MMTV-Cre* and *Ccn6^wt/wt^*;*MMTV-Cre* 8 week-old mice mammary glands. For all experiments quantification was performed blindly to genotype by two independent investigators with results reported as average ± SEM, n= at least 3 mice per genotype, in triplicate. Two tailed Student's t test \*P\<0.05. (Scale bars, 20 µm.)](nihms815638f3){#F3}

![*Ccn6* KO mice exhibit residual persistent brown adipose tissue (BAT) and terminal end bud (TEB)-like structures at 8 months of age\
**A**. Histological H&E sections from 8 month-old virgin *Ccn6^wt/wt^;MMTV-Cre* and *Ccn6^fl/fl^;MMTV-Cre* mice. Note the presence of brown adipose tissue (BAT) in *Ccn6^fl/fl^;MMTV-Cre* mice. **B**. Quantification of the prevalence of BAT in the mammary whole mounts of virgin mice. **C**. Mammary whole mounts of 8 month-old *Ccn6^fl/fl^;MMTV-Cre* and *Ccn6^wt/wt^;MMTV-Cre* mice show the persistence of TEB-like structures in *Ccn6^fl/fl^;MMTV-Cre* mice. **D**. Bars show the prevalence of TEB-like structures, n=at least 3 mice per genotype. Two-tailed Fischer's exact tests were used for all statistical analyses. \**P*\<0.05.](nihms815638f4){#F4}

![*Ccn6* deletion induces mammary tumors morphologically similar to human spindle metaplastic carcinomas and enhances distant metastasis\
**A**. Histological sections of *Ccn6^fl/fl^;MMTV-Cre* mammary tumors (a-f) showing a strikingly spindle cell morphology and high tumor grade. In (f) the carcinoma infiltrates skeletal muscle. 400x magnification. **B**. Histological sections of non-neoplastic mammary glands of *Ccn6^fl/fl^;MMTV-Cre* mice adjacent to invasive carcinomas showing atypical ductal hyperplasia, secretory hyperplasia and residual TEBs. **C**. Representative images of fresh lungs of *Ccn6^fl/fl^*;*PyMT* and *Ccn6^wt/wt^;PyMT* mice. Arrows indicate grossly identified metastasis. Below are histological sections of the lungs showing metastatic nodules, 100x magnification. **D**. Number of macroscopic lung metastasis and primary tumor volume in *Ccn6^fl/fl^*;*PyMT* and *Ccn6^wt/wt^*;*PyMT* mice. Shown is also CCN6 mRNA expression by quantitative RT-PCR in primary mammary tumors. \*\**P*\<0.005, two-tailed Student's t test. (Scale bars, 50 µm.)](nihms815638f5){#F5}

![Mammary carcinomas in *Ccn6^fl/fl^;MMTV-Cre* mice share an 87 gene signature with human metaplastic carcinomas\
**A**. Venn diagram showing the overlapping 87 orthologous genes between *Ccn6^fl/fl^;MMTV-Cre* tumors and a previously reported profile of human high grade metaplastic carcinomas ([@R11]) (*p*= 5×10^−11^ for the overlap). Of the 2,930 orthologous genes with at least 2-fold up or down regulation in *Ccn6^fl/fl^;MMTV-Cre* tumors compared to *Ccn6^wt/wt^;MMTV-Cre* mammary glands, 87 showed significant overlap with the human metaplastic carcinoma signature ([@R11]). **B**. Heatmap of the 87 overlapping orthologous genes. **C**. Representative images *Ccn6^fl/fl^;MMTV-Cre* mice mammary carcinomas immunostained with anti-Ccn6 and clinically used markers of human metaplastic carcinoma. Arrowheads point to a normal gland entrapped by the spindle metaplastic carcinoma. 400x magnification. (Scale bars, 50 µm.)](nihms815638f6){#F6}

###### 

Histopathological features of 13 mammary carcinomas from *Ccn6^fl/fl^* virgin female mice.

  ---------------------------------------------------------------------------------------------------
  Tumor   Age\       Histology        Tumor\   EMT   Metastasis    Non-neoplastic mammary\
          (months)                    grade                        gland
  ------- ---------- ---------------- -------- ----- ------------- ----------------------------------
  1       10         Spindle with\    3        Yes   \-            Atypical hyperplasia
                     necrosis                                      

  2       12         Spindle          3        Yes   Soft tissue   Atypia, residual TEBs

  3       13         Spindle          3        Yes   \-            Secretory hyperplasia

  4       13         Glandular and\   3        Yes   \-            Hyperplasia
                     spindle                                       

  5       14         Spindle          3        Yes   Lung          Atypia

  6       14         Spindle,\        3        Yes   Lung          Secretory hyperplasia
                     squamous and\                                 
                     glandular                                     

  7       15         Spindle          3        Yes   \-            Secretory hyperplasia and atypia

  8       16         Spindle with\    3        Yes   Lung          Secretory hyperplasia and atypia
                     necrosis                                      

  9       16         Spindle          3        Yes   Lung          Severe atypia

  10      18         Spindle and\     3        Yes   \-            Secretory hyperplasia
                     nested                                        

  11      19         Spindle          3        Yes   \-            Secretory hyperplasia

  12      21         Spindle          3        Yes   Lung          Secretory hyperplasia, atypia

  13      21         Spindle          3        Yes   \-            Atypia, residual TEBs
  ---------------------------------------------------------------------------------------------------

###### 

Summary of selected genes significantly deregulated in *Ccn6^fl/fl^* mammary tumors and in human metaplastic carcinomas. \*Average gene expression ratios (log2-transformed) between the human and mouse tumors.

  Unigene                                        Gene symbol             Fold Change                                                          
  ---------------------------------------------- ------------- --------- ------------- ----------------------------------------------- ------ ------
  Morphogenesis of an epithelium                                                                                                              
  Hs.631988                                      Mm.5021       *DDR1*    *Ddr1*        Discoidin domain receptor family, member 1      0.46   0.32
  Hs.461086                                      Mm.35605      *CDH1*    *Cdh1*        Cadherin 1                                      0.24   0.13
  Hs.76753                                       Mm.225297     *ENG*     *Eng*         Endoglin                                        0.60   0.33
  Hs.40735                                       Mm.214687     FZD3      *Fzd3*        Frizzled homolog 3 (Drosophila)                 0.49   0.47
  Hs.799                                         Mm.289681     HBEGF     *Hbegf*       Heparin-binding EGF-like growth factor          1.93   5.13
  Hs.163484                                      Mm.4578       FOXA1     *Foxa1*       Forkhead box A1                                 0.05   0.10
  Hs.233950                                      Mm.104955     SPINT1    *Spint1*      Serine protease inhibitor, Kunitz type 1        0.62   0.24
  Hs.513530                                      Mm.3248       TGFB1I1   *Tgfb1i1*     TGF beta 1 induced transcript 1                 0.60   0.39
                                                                                                                                              
  Embyo development                                                                                                                           
  Hs.603657                                      Mm.441439     ELF3      *Elf3*        E74-like factor 3                               0.25   0.43
  Hs.654568                                      Mm.439699     KRT19     *Krt19*       Keratin 19                                      0.30   0.17
  Hs.149387                                      Mm.4040       MYO6      *Myo6*        Myosin VI                                       0.35   0.19
  Hs.498494                                      Mm.294007     PCSK6     *Pcsk6*       Proprotein convertase subtilisin/kexin type 6   0.64   0.15
                                                                                                                                              
  Lateral plasma membrane                                                                                                                     
  Hs.647023                                      Mm.158662     CLDN3     *Cldn3*       Claudin 3                                       0.28   0.16
  Hs.647036                                      Mm.7339       CLDN4     *Cldn4*       Claudin 4                                       0.43   0.35
                                                                                                                                              
  Cellular amino acid metabolic process                                                                                                       
  Hs.301961                                      Mm.37199      GSTM1     *Gstm1*       Glutathione S-transferase, mu 1                 0.51   0.31
  Hs.595276                                      Mm.34064      STAT5B    *Stat5b*      Signal trans. & activator of transcription 5B   0.62   0.19
  Hs.126688                                      Mm.259916     CHDH      *Chdh*        Choline dehydrogenase                           0.42   0.33
  Hs.461954                                      Mm.131443     SRR       *Srr*         Serine racemase                                 0.65   0.25
  Hs.262823                                      Mm.331142     IARS2     *Iars2*       Isoleucine-tRNA synthetase 2, mitochondrial     0.52   0.37
  Hs.227049                                      Mm.2065       CTPS2     *Ctps2*       Cytidine -triphosphate synthase 2 5'            0.57   0.50
  Hs.513646                                      Mm.6635       IVD       *Ivd*         Isovaleryl coenzyme A dehydrogenase             0.61   0.16
                                                                                                                                              
  Very long-chain fatty acid catabolic process                                                                                                
  Hs.700576                                      Mm.399042     ABCD3     Abcd3         ATP-binding cassette, sub-family D, member 3    0.38   0.27
  Hs.656699                                      Mm.330113     SLC27A4   Slc27a4       Solute carrier family 27, member 4              0.53   0.41
